Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

A comprehensive review on gelatinous transformation of the bone marrow
Gunaratne, Madugodaralalage D. S. K. , Shi, Min , Go, Ronald S.

Expert Review of Hematology | July 26, 2024 | Volume: 17 | Issue: 9 | Pages: 547-554

10.1080/17474086.2024.2385472 | PMID 39060221 Get It

A case of left posterior cortical atrophy presenting with kana-predominant reading impairment
Nakatani, Natsuki , Ono, Daisuke , Hirata, Kosei , Yoshioka, Kotaro , Endo, Hironobu, Higuchi, Makoto , Endo, Hironobu , Ono, Kenjiro , Yokota, Takanori

Rinsho Shinkeigaku | July 26, 2024 | Volume: 64 | Issue: 8 | Pages: 557-563

10.5692/clinicalneurol.cn-001907 | PMID 39069492 Get It

Novel method of iliac accessory rods for rod fracture prevention in adult deformity surgery: a case series of 82 patients with outcomes and complications
Berlin, Connor , Ben‐Israel, David , Park, Brian J. , Yen, Chun-Po , Shaffrey, Mark E., Sardi, José , Ibrahim, Sufyan , Smith, Justin S.

Journal of Neurosurgery: Spine | July 26, 2024 | Volume: 43 | Issue: 4 | Pages: 424-432

10.3171/2024.5.spine24208 | PMID 39059456 Get It

OBJECTIVE Primary rod fracture after surgery for adult spinal deformity (ASD) is a leading cause of revision, with recent prospective multicenter fracture rates reported at 11%–14% by 2 years. Consequently, the addition of supplemental rods has been explored to reduce fractures. Here the authors describe their experience with a novel iliac accessory rod technique in which each accessory rod anchors to an independent iliac bolt caudally via lateral connector, and attaches to the primary rod rostrally via side-to-side connector. METHODS This retrospective, single-center case series included patients who underwent thoracolumbar/lumbar fusion for ASD between March 2019 and August 2023. Data on baseline demographics, radiographic parameters, surgical characteristics, complications, rod fracture, and revision rates were collected. Paired, 2-tailed t-tests were used to compare pre- and postoperative radiographic outcomes. Rod fracture rates were compared to prior investigations via chi-square goodness of fit testing. The technique for iliac accessory rod placement is described. RESULTS The study consisted of 82 patients (mean age 66 years, 51% female, 26% with prior fusion) with a median follow-up of 2 years (IQR 28–104 weeks). A total of 50 patients (61%) had ≥ 2-year follow-up. Each surgery involved an average of 4 posterior column osteotomies and 8 segments. Iliac accessory rods were cobalt chromium and were placed bilaterally in 87% of constructs. Postoperative alignment improved significantly in the following parameters: maximum coronal Cobb angle, fractional curve, sagittal vertical axis, lumbar lordosis, thoracic kyphosis, and pelvic incidence to lumbar lordosis mismatch (p < 0.001 for all comparisons). Of 50 patients with ≥ 2-year follow-up, rod fracture occurred in 1 (2.0%), which was incidentally found and required no intervention. The present rod fracture rate was significantly lower than the authors’ historically reported institutional rate of 21% for traditional dual-rod constructs, and the 11%–14% reported in recent prospective multicenter studies that used traditional and supplemental rod constructs (p < 0.05 for all comparisons). Reoperation occurred in 12 patients (14.6%); 7 (8.5%) for proximal junctional kyphosis and 5 (6.1%) for wound complication. CONCLUSIONS Here the authors describe their experience with a novel iliac accessory rod technique to prevent rod fracture in patients undergoing surgery for ASD. The 2-year rod fracture rate (2.0%) in this study is significantly lower than the authors’ historical dual-rod fracture rate, and other prospective multicenter investigations. Future studies with longer follow-up are needed to determine the durability of this technique.
Post-Traumatic Reactions and Quality of Life after Pelvic Exenteration for Gynecologic Cancer: A Retrospective Cohort Study
Thompson, Lora M.A., Albizu‐Jacob, Alexandra , Chon, Hye Sook, Wenham, Robert M. , Donovan, Kristine A. , Loecher, Nele

No container title available | July 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4492643/v1 Get It

Abstract Objective: We examined post-traumatic reactions and quality of life in women with recurrent gynecologic cancer who underwent a pelvic exenteration (PE), a rare, potentially life-saving radical surgery associated with life-altering sequalae. Methods: Twenty-one women who had completed PE at least 6 months prior completed measures of post-traumatic stress, post-traumatic growth, depression, and quality of life. Quality of life scores were compared to normative values for the general and gynecologic cancer populations. Results: Thirty percent of women reported clinically significant post-traumatic stress symptoms and 71% endorsed clinically significant depressive symptoms. More post-traumatic stress was associated with less post-traumatic growth, more depressive symptoms, and worse quality of life. In general, women’s quality of life was worse than the general population but comparable to women with stage III-IV ovarian cancer and women with cervical cancer. Social functioning was markedly lower in our sample and women reported more pain, diarrhea, and financial difficulties post-PE compared to published norms. There were no differences in quality of life based on age, type of PE, or cancer type. Conclusions: Findings support long-term continued symptom management and the ongoing rehabilitation of patients to optimize physical, psychological, and social well-being in PE survivorship.
Central α2‐adrenergic mechanisms regulate human sympathetic neuronal discharge strategies
Klassen, Stephen A. , Limberg, Jacqueline K. , Iannarelli, Nathaniel , Senefeld, Jonathon W. , Nicholson, Wayne T. , Joyner, Michael J. , Shoemaker, J. Kevin , Curry, Timothy B. , Shoemaker, J Kevin , Joyner, Michael J , Senefeld, Jonathon W , Klassen, Stephen A , Harvey, Ronée E. , Wiggins, Chad C. , Baker, Sarah E.

The Journal of Physiology | July 26, 2024 | Volume: 602 | Issue: 16 | Pages: 4053-4071

10.1113/jp286450 | PMID 39058701 Get It

AbstractThe present study investigated the impact of central α2‐adrenergic mechanisms on sympathetic action potential (AP) discharge, recruitment and latency strategies. We used the microneurographic technique to record muscle sympathetic nerve activity and a continuous wavelet transform to investigate postganglionic sympathetic AP firing during a baseline condition and an infusion of a α2‐adrenergic receptor agonist, dexmedetomidine (10 min loading infusion of 0.225 µg kg−1; maintenance infusion of 0.1–0.5 µg kg h−1) in eight healthy individuals (28 ± 7 years, five females). Dexmedetomidine reduced mean pressure (92 ± 7 to 80 ± 8 mmHg, P < 0.001) but did not alter heart rate (61 ± 13 to 60 ± 14 bpm; P = 0.748). Dexmedetomidine reduced sympathetic AP discharge (126 ± 73 to 27 ± 24 AP 100 beats−1, P = 0.003) most strongly for medium‐sized APs (normalized cluster 2: 21 ± 10 to 5 ± 5 AP 100 beats−1; P < 0.001). Dexmedetomidine progressively de‐recruited sympathetic APs beginning with the largest AP clusters (12 ± 3 to 7 ± 2 clusters, P = 0.002). Despite de‐recruiting large AP clusters with shorter latencies, dexmedetomidine reduced AP latency across remaining clusters (1.18 ± 0.12 to 1.13 ± 0.13 s, P = 0.002). A subset of six participants performed a Valsalva manoeuvre (20 s, 40 mmHg) during baseline and the dexmedetomidine infusion. Compared to baseline, AP discharge (Δ 361 ± 292 to Δ 113 ± 155 AP 100 beats−1, P = 0.011) and AP cluster recruitment elicited by the Valsalva manoeuvre were lower during dexmedetomidine (Δ 2 ± 1 to Δ 0 ± 2 AP clusters, P = 0.041). The reduction in sympathetic AP latency elicited by the Valsalva manoeuvre was not affected by dexmedetomidine (Δ –0.09 ± 0.07 to Δ –0.07 ± 0.14 s, P = 0.606). Dexmedetomidine reduced baroreflex gain, most strongly for medium‐sized APs (normalized cluster 2: –6.0 ± 5 to –1.6 ± 2 % mmHg−1; P = 0.008). These data suggest that α2‐adrenergic mechanisms within the central nervous system modulate sympathetic postganglionic neuronal discharge, recruitment and latency strategies in humans. imageKey points Sympathetic postganglionic neuronal subpopulations innervating the human circulation exhibit complex patterns of discharge, recruitment and latency. However, the central neural mechanisms governing sympathetic postganglionic discharge remain unclear. This microneurographic study investigated the impact of a dexmedetomidine infusion (α2‐adrenergic receptor agonist) on muscle sympathetic postganglionic action potential (AP) discharge, recruitment and latency patterns. Dexmedetomidine infusion inhibited the recruitment of large and fast conducting sympathetic APs and attenuated the discharge of medium sized sympathetic APs that fired during resting conditions and the Valsalva manoeuvre. Dexmedetomidine infusion elicited shorter sympathetic AP latencies during resting conditions but did not affect the reductions in latency that occurred during the Valsalva manoeuvre. These data suggest that α2‐adrenergic mechanisms within the central nervous system modulate sympathetic postganglionic neuronal discharge, recruitment and latency strategies in humans.
Impact of Sociodemographic Disparities on Sarcopenia, Telomere Length, and Mortality in Patients with Liver Disease in the US Population
Kassmeyer, Blake , Lennon, Ryan J. , Kamath, Patrick S. , Shah, Vijah, Kezer, Camille A. , Kusztos, Victoria , Rattan, Puru , Shah, Vijay H. , Simonetto, Douglas A.

No container title available | July 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4670813/v1 Get It

Abstract Background & Aims: Sarcopenia is common in patients with liver disease and both sarcopenia and short telomeres are associated with mortality, however their relationship in patients with liver disease remains unknown. Methods: A cohort of 16,072 adults from the National Health and Nutrition Examination Survey from 1999-2006 was analyzed. Liver disease was defined by aminotransferases and classified into etiology-based categories. Sarcopenia was defined by dual-energy x-ray absorptiometry. All analyses were conducted separately on each multiple imputation data set and combined via Rubin’s rules. P-values for group comparisons were calculated by testing logistic regression parameter estimates. Cox proportional hazards regression was used for mortality analysis with mortality data available until 2015. Results:Sarcopenia was present in 9.5% of patients with liver disease. Age, race, income, education, physical inactivity, and certain medical comorbidities were associated with sarcopenia. Patients with liver disease and sarcopenia had significantly shorter telomeres than patients with liver disease without sarcopenia when unadjusted for age. The interaction between telomere length and sarcopenia was significantly associated with all-cause mortality. Conclusions: The implications of telomere length on all-cause mortality in patients with liver disease varied by age and sarcopenia status. Shorter telomeres appear to be more highly associated with increased mortality in older patients without sarcopenia.
Diagnosis of Renal Tumors in Birt-Hogg-Dube Syndrome: Clinical Presentation and Risk Factors in a Single-center Retrospective Cohort
Kijlertsuphasri, Supiya, Moua, Teng , Petnak, Tananchai

No container title available | July 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4651079/v1 Get It

Abstract Background: Birt-Hogg-Dube (BHD) syndrome is a rare genetic condition associated with the development of renal tumors. This study aims to determine typical age ranges for detecting renal abnormalities, risk factors for tumor development, and long-term outcomes based on current surveillance strategies. Methods: A single-center multi-site retrospective cohort study was performed on all patients with BHD diagnosed from 2000 to 2023. Baseline demographics, pulmonary function, laboratory, radiologic, and histopathologic findings were collected. Logistic regression was used to assess predictor variables for the development of renal tumors with survival analysis evaluated from the date of BHD diagnosis to date of death or last known follow-up. Results: The study included 149 patients with BHD, 39 (26%) with diagnosed renal tumors, of which 28 had histopathologic confirmation. Mean age at renal tumor detection was 53.61 years. Older age and male sex were predictive of renal tumor development ((odds ratio 1.05; 95% CI, 1.01-1.08, P = 0.002) and (odds ratio 2.59; 95% CI, 1.17-5.73, P=0.02), respectively). Time to all-cause mortality appeared shorter in those with renal tumors (Log-rank P = 0.02), though no deaths were from cancer or cancer-related complications. Conclusions: Current screening protocols for renal tumors in BHD suggest the most common presenting age range for presentation is late 40s to early 50s, with older age and male sex as risk factors for tumor development.
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round
Patel, Bhavika , Carnahan, Molly B. , Northfelt, Donald W. , Anderson, Karen S. , Mazza, Gina L. , Pizzitola, Victor J. , Giurescu, Marina E., Lorans, Roxanne, Eversman, William G. , Sharpe, Richard E. , Harper, Laura , Apsey, Heidi A., Palmieri, Jennifer, Fraker, Jessica , Mina, Lida A. , Pockaj, Barbara A. , Patel, Bhavika K , Northfelt, Donald , Harper, Laura K , Apsey, Heidi, Kling, Juliana M , Ernst, Brenda , Fraker, Jessica , Mina, Lida, Batalini, Felipe , Pockaj, Barbara, Mazza, Gina L , Harrison, Molly , Cronin, Patricia A. , Kling, Juliana M. , Ernst, Brenda , Batalini, Felipe

Journal of Clinical Oncology | July 26, 2024 | Volume: 42 | Issue: 32 | Pages: 3826-3836

10.1200/jco.22.02819 | PMID 39058970 Get It

PURPOSE Contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) have shown similar diagnostic performance in detection of breast cancer. Limited CEM data are available for high-risk breast cancer screening. The purpose of the study was to prospectively investigate the efficacy of supplemental screening CEM in elevated risk patients. MATERIALS AND METHODS A prospective, single-institution, institutional review board–approved observational study was conducted in asymptomatic elevated risk women age 35 years or older who had a negative conventional two-dimensional digital breast tomosynthesis screening mammography (MG) and no additional supplemental screening within the prior 12 months. RESULTS Four hundred sixty women were enrolled from February 2019 to April 2021. The median age was 56.8 (range, 35.0-79.2) years; 408 of 460 (88.7%) were mammographically dense. Biopsy revealed benign changes in 22 women (22/37, 59%), high-risk lesions in four women (4/37, 11%), and breast cancer in 11 women (11/37, 30%). Fourteen cancers (10 invasive, tumor size range 4-15 mm, median 9 mm) were diagnosed in 11 women. The overall supplemental cancer detection rate was 23.9 per 1,000 patients, 95% CI (12.0 to 42.4). All cancers were grade 1 or 2, ER+ ERBB2–, and node negative. CEM imaging screening offered high specificity (0.875 [95% CI, 0.844 to 0.906]), high NPV (0.998 [95% CI, 0.993 to 1.000), moderate PPV1 (0.164 [95% CI, 0.076 to 0.253), moderate PPV3 (0.275 [95% CI, 0.137 to 0.413]), and high sensitivity (0.917 [95% CI, 0.760 to 1.000]). At least 1 year of imaging follow-up was available on all patients, and one interval cancer was detected on breast MRI 4 months after negative screening CEM. CONCLUSION A pilot trial demonstrates a supplemental cancer detection rate of 23.9 per 1,000 in women at an elevated risk for breast cancer. Larger, multi-institutional, multiyear CEM trials in patients at elevated risk are needed for validation.
Pain intensity and opioid consumption after temporary and permanent peripheral nerve stimulation: a 2-year multicenter analysis
West, Tyler , Hussain, Nasir , Bhatia, Anuj , Kilgore, Anthony E, Palettas, Marilly , Javed, Saba , D’Souza, Ryan S. , ElSaban, Mariam , D'Souza, Ryan S , Bhatia, Anuj , Kilgore, Anthony E., Abdel‐Rasoul, Mahmoud , Javed, Saba

Regional Anesthesia & Pain Medicine | July 26, 2024 | Volume: 50 | Issue: 11 | Pages: 865-872

10.1136/rapm-2024-105704 | PMID 39060006 Get It

Objective Peripheral nerve stimulation (PNS) is an emerging neuromodulation modality, yet there remains limited data highlighting its long-term effectiveness. The objective of this study was to report real-world data on pain intensity and opioid consumption after temporary and permanent PNS for chronic pain up to 24 months postimplantation. Methods A retrospective study was conducted on all patients who received PNS implants at a multi-centered enterprise between January 1, 2014 and February 24, 2022. The two co-primary outcomes were: (1) change in pain intensity (11-point Numerical Rating Scale) from baseline to 12 months postimplant; and (2) comparison of the change in pain intensity between temporary and permanent PNS cohorts 12 months postimplant. Results 126 patients were included in this analysis. Pain intensity significantly decreased 12 months postimplant in the overall cohort (mean difference (MD) −3.0 (95% CI −3.5 to −2.4), p<0.0001). No significant difference in this reduction was identified between temporary and permanent PNS cohorts (MD 0.0 (95% CI −1.1 to 1.0), p=1.00) 12 months postimplantation. Pain intensity significantly decreased in the overall, temporary, and permanent cohorts at all secondary time points (3, 6, and 24 months). No change in daily opioid consumption was observed at 6 and 12 months postimplant in the overall cohort. Conclusion This study found that both temporary and permanent PNS may be effective for reducing pain intensity in patients with chronic pain up to 24 months postimplantation, although no changes in opioid consumption were observed. The decrease in pain intensity was comparable between patients receiving temporary versus permanent implants, highlighting that temporary PNS may achieve long-lasting clinical benefits. However, given the substantial loss to follow-up, further large-scale studies are needed to solidify conclusions about the efficacy of PNS.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Johnson, Douglas B. , Albertini, Mark R. , Barker, Christopher A. , Bateni, Sarah B. , Baumgartner, Joel , Bichakjian, Christopher K. , Chandra, Sunandana , DiMaio, Dominick J. , Dronca, Roxana , Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hyngstrom, John , Karakousis, Giorgos C. , Kendra, Kari , Lange, Julie R., Lanning, Ryan M. , Logan, Theodore F. , Ott, Patrick A. , Ross, Merrick I. , Skitzki, Joseph J. , Smith, Emily , Tsai, Katy K., Wuthrick, Evan , Xing, Yan, McMillian, Nicole R., Espinosa, Sara, Olson, Daniel J. , Swetter, Susan M. , Bhatia, Shailender , Boland, Genevieve M. , Chmielowski, Bartosz , Fields, Ryan C. , Kiuru, Maija H. , Olson, Daniel, Olszanski, Anthony J. , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit R. , Xing, Yan, Olson, Daniel

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 290-298

10.6004/jnccn.2024.0036 | PMID 39019054 Get It

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous ) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.